International Journal of Science and Research (IJSR) ISSN: 2319-7064

SJIF (2022): 7.942

Monkeypox Virus Disease

Dr. Manisha Danane

BHMS - Bachelor of Homeopathic Medicine and Surgery, ACLS - Advance Cardiac Life Support, BLS - Basic Life Support, EMS - Emergency Medicine Services, Maharashtra, India

Abstract: 12th July, India got its first patient detected positive for monkeypox who had travelled to U. A. E. few days back. Monkeypox updated as on July 10, 611 confirmed cases reported in 65 countries. CDC is trying to alert patients who have rash illness consistent with monkeypox regardless whether they have travelled or specific risk factors for monkeypox and gender or sexual orientation. CDC is contact tracing now to identify who may have been in contact with people who have tested positive for monkeypox so they can monitor their health, and also tracking several countries where that don't normally report monkeypox, it is advised to wear PPE Kit (personal protective equipment) for all health care workers. Patient with monkeypox should isolate at home. Vaccination is recommended. Either with ACAM2000 or JYNNEOS to protect them if they have exposed to an orthopoxvirus, this is known as exposure prophylaxis (PrEP). Proper data is not yet available. People is considered fully vaccinated about 2 weeks after their second shot of JYNNEOS and 4 weeks after receiving ACAM2000, Even after vaccination preventive steps are required to be taken

Keywords: monkeypoxvirus, vaccination, CDC, PPE

1. Introduction



First case age 35yr of mokeypox is detected in India on 12 July 2022, patient had Travelled from UAE to India, one of his friend was found to be positive few days ago, the patients is recuperating well, the Kerala government has informed. First outbreak of monkeypox had occurred in 2003 in western hemisphere, it was referred to pet dogs imported from Ghana and were kept with other rodents. Monkeypox virus was named from where it was originally, isolated and rodents were primary viral reservoir. Zoonoses are infection transmitted from animal to humans, its most re-emerging human pathogen. IT'S found in Africa mostly tropical rainforest regions.

Monkeypox is a viral zoonotic (infection transfer from animals to humans) disease, identified in animals - Rodents, Rope Squirrels, Tree squirrels, Gambian porched rats, Dormice, African Dormouse, sooty Mangabey, Non-Human primates. Near about 1200 cases from 12 non endemic countries and 82 suspected cases in 32 endemic countries as estimated by world health organisation, on 09 June. The clinical presentation of monkey pox resembles to that of smallpox, a related orthopoxviral infection which was declared eradicated worldwide in 1980. Monkeypox is less contagious than smallpox and causes less severe illness.

| Orthopox virus genus | Monkeypox virus |
|---------------------------|--------------------------|
| Species | Extinct Africa |
| Host Reservoir | Rodents |
| Family | Poxviride |
| Human Disease | Smallpox like systematic |
| Natural host of Monkeypox | Not known |

Environmental and Social Factors of Emergence

Deforestation Civil unrest and poverty Climate change Cessation of smallpox vaccination

Monkeypox virus -

Non Endemic Countries: Australia, Belgium, Canada, Germany, France, Italy, PORTUGAL, Spain, Sweden, U. K., U. S. A.

Endemic Countries: Benin, Cameroon, the Central African, Republic, the Democratic Republic of the Congo, Gabon, Ghana, (identified in animals only), Ivory, Coast, Liberia, Nigeria, the Republic of the Congo, Sierra Leone and South Sudan.



Countries affected by monkeypox

Recent outbreaks of monkeypox – a viral infection typically found in west and central Africa – are occurring in countries that would not normally expect to have the disease



Monkey pox is usually a self limited disease, with symptoms lasting from 2 to 4 weeks. Monkey pox can be transmitted from animals to humans as well as human to human. The virus enters the body through broken skin, respiratory tract or mucus membranes (eyes, nose, or mouth). Animal to human transmission may occur by bite or scratch, bushmeat preparation (Bushmeat is meat from wildlife species), direct contact with body fluids or lesions material, or indirect contact with lesion material, such as through contaminated bedding. Incubation period is usually 7-14 days but can range from F 5-21 days and the person is usually not contagious during this period.

An infected person may transmit the decision from 1-2 days before appearance of the rash and remain contagious till all the scabs fall off.

Modes of transmission:

Unprotected contact with Respiratory droplets Lesion material Body fluids Contaminated materials and surfaces

Virus enters through:-

Respiratory track Mucous membrane - eyes, mouth Broken skin (animal bite)

Clinical Features:

Monkeypox virus - Fever, Rash, and lymphadenopathy, 12 days after the exposure, Sorethroat, malaise, fatigue, Virus present in blood is (viremia), at the end of incubation period. small lesions in mouth (enanthem) appear towards the end

Stages:-

Macule-papule-vesicle-pustule-crust

| 5-12 days | Incubation period | |
|---------------|-------------------|--|
| 1-4 days | Febrile stage | |
| 2-4 weeks | Rash stage | |
| Days to weeks | Recovery | |



Infographic by Rafa Estrada Source: Singapore Ministry of Health, US Centers for Disease Control and Prevention

Complications:

Corneal infection and vision loss Secondary bacterial infection Abscess and airway obstruction Pneumonia Bacterial infection of the blood-sepsis Inflammation of the brain - Encephalitis miscarriage

Fatality ratio - 10% death

Long term consequences:-Scarring Reduced skin pigmentation Blindness Asymptomatic infection may occur.

Risk factor for severe illness:-Children Immunodeficiency Invasive rate of infection Congo basin clade variant.

Differential diagnosis:-

Cowpox Buffalopox

| | monkeypox | chickenpox | measles | |
|-------------------|-----------------------------|-----------------------------|---------------------------------------|--|
| Fever | 1-3 days before rash | 1-2 days before rash | 3-5 days before rash | |
| Rash appearance | Lesions often in one stage | Lesions often in multiple | Lesions often in multiple stages of | |
| | of development | stages of development | development | |
| Rash development | slow | rapid | rapid | |
| Rash distribution | More dense of face; present | More dense on truck; absent | Starts on face and spreads, sometimes | |
| | on palms and soles | on palm's and sole | reaching hands and feet | |
| lymphadenopathy | present | absent | occasional | |
| Death | Up to 10% | rare | Varies widely | |

Laboratory test:

PCR - Polymerase chain reaction, is the technique most commonly used to confirm monkeypox Tests conducted on lesions material.

DNA Test: to detect monkeypox and viral clade.

Virus isolation: detect viral particles

Electron microscopy: reveals virus morphology

Antigen detection: it uses an antibody directed against on Orthopoxvirus antigen, proves the presence of an Orthopox virus current infection, done on Lesion test - not monkeypox virus specific

Antibody detection: antigen directed against the antibodies limited diagnostic value proves a reaction of the body to the

Volume 11 Issue 7, July 2022

<u>www.ijsr.net</u>

Licensed Under Creative Commons Attribution CC BY

virus current or past infection or vaccination done on serum not monkeypox virus specific.

Case definition:

Suspected case:-

Probable case:

A suspected case with an epidemiology link of a confirmed case or another probable case

Confirmed case:-

Has lab confirmed

Fever >38.3'C, headache, lymphadenopathy, myalgia, distinctive and progressive rash, including on hands and feet

| Condition | Treatment objective | Treatment and care Monitoring | | |
|--------------------|--------------------------------|---|--|--|
| Fever | Prevent and treat | External cooling, antipyretic medication | Regular temperature monitoring | |
| Skin | Prevent and treat secondary | oral or intravenous antibiotics' incision and | Fever, pain, tenderness, erythema, | |
| function | bacterial infections | drainage, advance wound management | oedema, exudate, warmth | |
| Ex foliation, skin | Avoid | Wash with soap and water or povidone - iodine | Lesion | |
| compromise | Scratching, minimize | solution | Count / rash burden. | |
| | insensible fluid loss, promote | Moist dressings and topical antibiotics e.g. silver | Skin turgor in non affected areas, | |
| | lesion healing | sulfadiazine or gentian violets | body weight, fluid intake/ output, | |
| | | Surgical debridement, skin grafts | | |
| Eye infection | Prevent corneal scarring and | Vitamin A supplementation | Repeat examination and vision | |
| | visual impairment | Ophthalmic antibiotics/antivirals | testing, | |
| | | Oral/ tropical analgesic medications | Slit lamp examination | |
| | | | | |
| Mouth and throat | Minimize mucosal pain, | Oral /topical analgesic medications | Lesion burden | |
| sores | Encourage | | Pain scale | |
| | Food intake, Promote lesion | | Food and fluid intake/ output | |
| Vamiting and | Minimiza fluid loss | Oral or introveneus rehudration | Enguanay and valuma of amagic and | |
| vonntnig and | Maintain nutrition | Oral or intravenous reliveration | diambase body weight ship types | |
| diarmoea | Maintain nutrition | Antidiambaal madiaatian | food and fluid intolso / output | |
| T | Minimine nain | | | |
| Lymphadenopathy | Reduce | inflommatory | Bain or tendernoss | |
| | Swellen lymph nodes | mediaation | Fail of tenderness | |
| Despiratory | Swohen Tymph hodes | Evotioning of negonhammy and simulate incentive | Despiratory | |
| symptoms or | Prevent and treat infactions | succioning of hasopharyix and an ways, incentive | Respiratory Pate and other vital sign's of distress | |
| distress | Prevent and manage | nebulizer treatment, oxygen and ventilation | such as indrawing shortness of | |
| 01501055 | respiratory distress | BiPAP or CPAP Intubation and Ventilation | breath pulse ovimetry | |
| sonsis | Hemodynamic stabilization | Oral/intravanous fluid antibictica | Dulse | |
| sepsis | riemouynamic staomzation | Oral/ Intravenous nutu antibiotics | F uise Blood pressure | |
| | | | Fluid status | |
| | | | Thuiu Status | |

International Journal of Science and Research (IJSR) ISSN: 2319-7064 SJIF (2022): 7.942

| System Affected/Syndrome | Treatment Objective | Therapeutic Considerations/Clinical Setting | | Follow-up/Monitoring |
|--|--|--|---|--|
| System Artected Syndione | | Developed | Low-Resource | ronow up monitoring |
| Respiratory tract | Maintain patent airways, prevent respiratory infection, atelectasis, and respiratory compromise | Suctioning of the nasopharynx and airways, incentive spirometry, chest physiotherapy, bronchodilation, oral/intravenous antibiotics for prophylaxis/treatment, nebulizer treatments, bronchoscopy, noninvasive ventilation (e.g., BiPAP or CPAP) ¹ , intubation/ventilation | Suctioning of the nasopharynx and airways, incentive spirometry, chest physiotherapy, bronchodilation, oral/intravenous antibiotics for prophylaxis/treatment | Respiratory rate, pulse oximetry |
| Sepsis | Hemodynamic stabilization | Oral/intravenous antibiotics, hemodynamic (e.g., intravenous fluid hydration and vasopressors), supplemental oxygen, corticosteroids, insulin | Oral/intravenous antibiotics, intravenous fluid hydration | Hemodynamic monitoring (e.g., pulse rate, blood pressure) |
| Gastrointestinal/mouth & throat sores | Minimize mucosal pain and disruption of food intake, promote lesion healing | Oral/topical analgesic medications | Oral/topical analgesic medications | Lesion burden, pain scale, food/fluid intake |
| Gastrointestinal/vomiting, diarrhea | Minimize gastrointestinal fluid losses | Oral/intravenous antiemetic and antidiarrheal medications, oral/intravenous rehydration | Oral/intravenous antiemetic and antidiarrheal medications, oral/intravenous rehydration | Frequency and volume of emesis and diarrhea, body weight, fluid intake/ouput |
| Fever | Prevent and treat episodes of fever | Antipyretic medications, external cooling | Antipyretic medications, external cooling | Routine temperature monitoring |
| Exfoliation, skin compromise | Minimize insensible fluid loss, promote lesion healing | Wash with soap and water or dilute water povidone-iodine solution, moisturized dressings, topical antibiotics (e.g., silver sulfadiazine), surgical debridement, skin grafts | Wash with soap and water or dilute water povidone-iodine solution, moisturized dressings, topical antibiotics (e.g., silver sulfadiazine) | Lesion count/rash burden, body weight, fluid intake/ouput |
| Superinfection skin | Prevention/treatment of secondary bacterial infections, promote lesion healing | Oral/intravenous antibiotics, incision and drainage, advanced wound management (e.g., negative pressure wound therapy) | Oral/intravenous antibiotics, incision and drainage | Fever, pain/tenderness, erythema, edema, exudate, warmth |
| Inflammation/lymphadenopathy | Minimize pain and decrease size of lymphadenopathy | Oral/intravenous anti-inflammatory/analgesic medications | Oral/intravenous anti-inflammatory/analgesic medications | Size of lymphadenopathy, pain/tenderness |
| Ocular infection | Prevent corneal scarring and vision impairment | Ophthalmic antibiotics/antivirals and corticosteroids; slit lamp examination | Ophthalmic antibiotics/antivirals and corticosteroids | Vision testing; repeat examination to |

Surveillance:

Mapping person, placed and time Detailed case investigation Specimen collection Primary and co-primary cases Secondary cases Epidemic prone disease

Notify health authorities immediately

Notifiable wide WHO International health regulation 2005, when unusual and unexpected

Local risk assessment:-

Core requirement Heightened control measures Lab worker must wear PPE KIT Vaccination for person's working with orthopox virus

2. Conclusion

- Isolated cases are seen in some part of US, UK, Singapore that means in non-endemic countries suggest Human to Human transmission could be present therefore further study is required whether virus has mutated and its ability to move widely
- 2) The spread of virus without epidemiology links suggest, Study of virus needs to be conducted
- 3) Current outbreak is behaving differently than earlier 1970-1980-year, study is requirement
- DNA of Monkeypox virus is 2000, 000 DNA Letters compared with 30, 000 RNA Letters of SARS CoV-2 IS Required to be studied, to rule out its mutation
- 5) Moderna is testing potential vaccines in pre-clinical trials for monkey pox virus

- 6) Maybe in future mass vaccination would be required but at present, public
- 7) The risk of human disease from animal orthopox virus infection may increase as smallpox immunity wanes in the general population and the popularity of exotic animals as household pets grow
- 8) Stigmatisind people because of a disease is not good
- 9) Anyone can get or pass on monkeypox
- 10) Monkeypox virus a New Pandemic



Bibliography:

GAVI-Global Alliance for Vaccine and Immunization GAVI - Dr Lee Hampton - medical epidemiologist World health organisation - Dr David Heyman-infectious disease specialist WHO-Monkeypox Outbox Tool ICMR - India Council of Medical Research - DR Aparna Mukherjee AII India Asian News International Brihanmumbai Municipal Corporation - Public Health Department Harrison's principles of internal medicine

CDC - Centers for disease control and prevention.

Volume 11 Issue 7, July 2022

<u>www.ijsr.net</u>

Licensed Under Creative Commons Attribution CC BY